Top

Published in:

01-02-2013 | SHORT REPORT

The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice

Authors: Valentina Rapozzi, Sonia Zorzet, Marina Zacchigna, Sara Drioli, Luigi E. Xodo

Published in: Investigational New Drugs | Issue 1/2013

Summary

Pheophorbide a (Pba) is a chlorophyll catabolite that has been proposed as photosensitizer in photodynamic therapy. In a previous study we conjugated Pba to monomethoxy-polyethylene glycol (mPEG-Pba), to increase its solubility and pharmacokinetics. Here, we compare the photodynamic therapy efficacy of free Pba and mPEG-Pba to cure a subcutaneous amelanotic melanoma transplanted in C57/BL6 mice. The photosensitizers, i.p. injected (30 mg/kg), showed no toxicity when the animals were kept in the dark. But, after photoactivation with a 660 nm laser (fluence of 193 J/cm²), both photosensitizers, in particular mPEG-Pba, showed a strong efficacy to cure the tumor, both in terms of tumor growth delay and increase of Kaplan-Meier median survival time. Together, our in vivo data demonstrate that mPEG-conjugated Pba is a promising photosensitizer for the photodynamic therapy of cancer.

Available only for authorised users

Dolmans DE, Fukimura D, Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3:380–387PubMedCrossRef

Dougherty TJ, Gomer CJ, Henderson BW et al (1998) Photodynamic therapy. J Natl Cancer Inst 90:889–905PubMedCrossRef

Pervaiz S (2001) Reactive oxygen-dependent production of novel photochemotherapeutic agents. FASEB J 15:612–617PubMedCrossRef

Juarranz A, Jaén P, Sanz-Rodríguez F et al (2008) Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 10:148–154PubMedCrossRef

Detty MR, Gibson SL, Wagner SJ (2004) Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem 47:3897–3915PubMedCrossRef

Schuitmaker JJ, Baas P, van Leengoed HL et al (1996) Photodynamic therapy: a promising new modality for the treatment of cancer. J Photochem Photobiol B 34:3–12PubMedCrossRef

Agostinis P, Berg K, Cengel KA et al (2011) Photodynamic therapy of cancer: an update. CA Cancer J Clin 61:250–281PubMedCrossRef

Derycke AS, Kamuhabwa A, Gijsens A et al (2004) Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. J Natl Cancer Inst 96:1620–1630PubMedCrossRef

Master AM, Qi Y, Oleinick NL et al (2011) EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies. Nanomedicine. doi:10.1016/j.nano.2011.09.012

10.

Abu-Yousif AO, Moor AC, Zheng X et al (2012) Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett. doi:10.1016/j.canlet.2012.01.014

11.

Giuntini F, Alonso CM, Boyle RW (2011) Synthetic approaches for the conjugation of porphyrin and related macrocycles to peptides and proteins. Photochem Photobiol Sci 10:759–791PubMedCrossRef

12.

Srivatsan A, Ethirajan M, Pandey SK et al (2011) Conjugation of cRGD peptide to chlorophyll a based photosensitizer (HPPH) alters its pharmacokinetics with enhanced tumor-imaging and photosensitizing (PDT) efficacy. Mol Pharm 8:1186–1197PubMedCrossRef

13.

Bhatti M, Yahioglu G, Milgrom LR et al (2008) Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. Int J Cancer 122:1155–1163PubMedCrossRef

14.

Van Dongen GA, Visser GW, Vrouenraets MB (2004) Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev 56:31–52PubMedCrossRef

15.

Gupta S, Dwarakanath BS, Chaudhury NK et al (2011) In vitro and in vivo targeted delivery of photosensitizers to the tumor cells for enhanced photodynamic effects. J Cancer Res Ther 7:314–324PubMedCrossRef

16.

Shieh YA, Yang SJ, Wei MF et al (2010) Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano 4:1433–1442PubMedCrossRef

17.

Zheng X, Pandey RK (2008) Porphyrin-carbohydrate conjugates: impact of carbohydrate moieties in photodynamic therapy (PDT). Anticancer Agents Med Chem 8:241–268PubMedCrossRef

18.

Di Stasio B, Frochot C, Dumas D et al (2005) The 2- aminoglucosamide motif improves cellular uptake and photodynamic activity of tetraphenylporphyrin. Eur J Med Chem 40:1111–1122PubMedCrossRef

19.

Gravier J, Schneider R, Frochot C et al (2008) Improvement of metatetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. Synthesis and in vivo delivery studies. J Med Chem 51:3867–3877PubMedCrossRef

20.

Hamblin MR, Miller JL, Rizvi I et al (2001) Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res 61:7155–7162PubMed

21.

Hamblin MR, Miller JL, Rizvi I et al (2003) Pegylation of charged polymer photosensitizer conjugates: effects on photodynamic efficacy. Br J Cancer 89:937–943PubMedCrossRef

22.

Chouikrat R, Seve A, Vanderesse R et al (2012) Non polymeric nanoparticles for photodynamic therapy applications: recent developments. Curr Med Chem 19:781–792PubMedCrossRef

23.

Wieder ME, Hone DC, Cook MJ et al (2006) Intracellular photodynamic therapy with photosensitizer-nanoparticle conjugates: cancer therapy using a 'Trojan horse'. Photochem Photobiol Sci 5:727–734PubMedCrossRef

24.

Stuchinskaya T, Moreno M, Cook MJ et al (2011) Targeted photodynamic therapy of breast cancer cells using antibody-phthalocyanine-gold nanoparticle conjugates. Photochem Photobiol Sci 10:822–831PubMedCrossRef

25.

Couleaud P, Morosini V, Frochot C et al (2010) Silica-based nanoparticles for photodynamic therapy applications. Nanoscale 2:1083–1095PubMedCrossRef

26.

Zhu Z, Tang Z, Phillips JA et al (2008) Regulation of singlet oxygen generation using single-walled carbon nanotubes. J Am Chem Soc 130:10856–10857PubMedCrossRef

27.

Huang P, Lin J, Yang D et al (2011) Photosensitizer-loaded dendrimer-modified multi-walled carbon nanotubes for photodynamic therapy. J Control Release 152(Suppl 1):e33–e34PubMedCrossRef

28.

Sortino S, Mazzaglia A, Monsù Scolaro L et al (2006) Nanoparticles of cationic amphiphilic cyclodextrins entangling anionic porphyrins as a “carrier-sensitizer” system in photodynamic cancer therapy. Biomaterials 27:4256–4265PubMedCrossRef

29.

McCarthy JR, Perez JM, Bruckner C et al (2005) Polymeric nanoparticle preparation that eradicates tumors. Nano Lett 5:2552–2556PubMedCrossRef

30.

Takamiya K, Tsuchiya T, Ohta H (2000) Degradation pathways of chlorophyll: what has gene cloning revealed? Trends Plan Sci 5:426–431CrossRef

31.

Rapozzi V, Zacchigna M, Biffi S et al (2010) Conjugated PDT drug. Photosensitizing activity and tissue distribution of PEGylated pheophorbide a. Cancer Biol Ther 10:1–12CrossRef

32.

Taub AF (2008) Photodynamic therapy in dermatology. In: Hamblin MR, Mroz P (eds) Advances in photodynamic therapy: basic, translational and clinical, Artech House, Boston, pp 419–442

33.

Soncin M, Busetti A, Reddi E et al (1997) Pharmacokinetic and phototherapeutic properties of axially substitued Si(IV)-tetradibenzobarreleno-octabutoxyphtalocyanines. J Photochem Photobiol B 40:163–167PubMedCrossRef

34.

Fabris C, Vicente MGH, Hao E et al (2007) Tumour-localizing and-photosensitizing properties of meso-tetra(4-nido-carboranylphenyl)porphyrin. J Photochem Photobiol B: Biol 89:131–136CrossRef

35.

Camerin M, Magaraggia M, Soncin M et al (2010) The in vivo efficacy of phthalocyanine-nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma. Eur J Cancer 46:1910–1918PubMedCrossRef

36.

Nelson JS, McCullough JL, Berns MW (1988) Photodynamic therapy of human- malignant melanoma xenografts in at hymic nude mice. J Natl Cancer Inst 80:56–60PubMedCrossRef

37.

Campaner P, Drioli S, Bonora GM (2006) Synthesis of selectively end-modified high-molecular weight polyethylenglycol. Lett Org Chem 10:773–779CrossRef

38.

Röeder B, Hanke TH, Oelckers ST et al (2000) Photophysical properties of pheophorbide a in solution and in a model membrane systems. J Porphyr Phtalocyanines 4:37–44CrossRef

39.

Sternberg ED, Dolphin D, Bruckner C (1998) Porphyrin based photosensitizers for use in photodynamic therapy. Tetrahedron 54:4151–4202CrossRef

40.

Xodo LE, Rapozzi V, Zacchigna M et al (2012) The chlorophyll catabolite pheophorbide a as a photosensitizer for the photodynamic therapy. Curr Med Chem 19:799–807PubMedCrossRef

41.

Tang PM, Zhang DM, Xuan NH et al (2009) Photodynamic therapy ninhibits p-glycoprotein mediated multidrug resistanve via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a. Mol Cancer 8:56–67PubMedCrossRef

42.

Rapozzi V, Miculan M, Xodo LE (2009) Evidence that photoactivated pheophorbide a causes in human cancer cells a photodynamic effect involving lipid peroxidation. Cancer Biol Ther 8:1318–1327PubMedCrossRef

43.

Hajri A, Wack S, Meyer C et al (2002) In vitro and in vivo efficacy of Photofrin and Pheophorbide a, a bacteriochlorin, in photodynamic therapy of colonic cancer cells. Photochem Photobiol 75:140–148PubMedCrossRef

44.

Hoi SW, Wong HM, Chan JY et al (2011) Photodynamic therapy of pheophorbide a inhibits the proliferation of human breast tumour via both caspase-dependent and -independent apoptotic pathways in in vitro and in vivo models. Phytother Res. doi:10.1002/ptr.3607

45.

Knop K, Hoogenboom R, Fischer D, Schubert US (2010) Poly(ethylene glycol) in drug delivery:pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 49:6288–6308PubMedCrossRef

46.

Rapozzi V, Umezawa K, Xodo LE (2011) Role of NF-kB/Snail/RKIP loop in the response of tumor cells to photodynamic therapy. Lasers Surg Med 43:575–585PubMed

47.

Torres M (2003) Mitogen-activated protein kinase pathways in redox signaling. Front Biosci 8:d369–d391PubMedCrossRef

48.

Landeer HM, Milbank AJ, Tauras JM et al (1996) Redox regulation of cell signaling. Nature 381:380–381CrossRef

49.

Chan WH (2011) Photodynamic therapy induces apoptotic pathway involving calcium, nitric oxide, p53, p21-activated kinase 2, and c-jun N-terminal kinase and inactivates survival signal in human umbilical vein endothelial cells. Int J Mol Sci 12:1041–1059PubMedCrossRef

50.

Berlett BS, Stadtman ER (1997) Protein oxidation in aging, disease and oxidative stress. J Biol Chem 272:20313–20316PubMedCrossRef

51.

Wiegell SR, Fabricius S, Stender IM et al (2011) A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½ h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol 164:1083–1090PubMedCrossRef

Title: The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice
Authors: Valentina Rapozzi
Sonia Zorzet
Marina Zacchigna
Sara Drioli
Luigi E. Xodo
Publication date: 01-02-2013
Publisher: Springer US
Published in: Investigational New Drugs / Issue 1/2013
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-012-9844-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 1/2013

Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases

Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent

Pemetrexed in patients with refractory soft tissue sarcoma: A non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005

Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent

Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel

A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer